Background: Cystic pancreatic endocrine tumors (CPETs) are rare lesions and their biological features have been scarcely investigated. Aim: To compare clinical and pathological features of resected non-functioning sporadic CPETs (NF-CPETs) with solid pancreatic endocrine tumors (SPETs) in a single-institution experience. Methods: All patients with a pathologically confirmed diagnosis of sporadic non-functioning pancreatic endocrine tumors who underwent curative resection between 1990 and 2008 were included. A comparison of demographic, clinical and pathological characteristics between CPETs and SPETs was made. Univariate and multivariable analyses were performed to identify preoperative predictors of carcinoma (non-functioning pancreatic endocrine carcinoma). Results: Twenty-one (11.5%) patients with a histological diagnosis of NF-CPET were identified. The median age was 60 years (IQR 46.5–73.5 years) and a diagnosis of carcinoma (non-functioning pancreatic endocrine carcinoma) was made in 3 (14.3%) cases. In the comparison with NF-SPETs, no differences were found in terms of gender (p = 0.75), age (p = 0.81), presenting symptoms (p = 0.43), localization of the tumors (p = 0.46) and type of resection (p = 0.31). The incidence of non-functioning pancreatic endocrine carcinoma was significantly lower in the NF-CPET versus the NF-SPET group (14.3 vs. 40.4%, p = 0.04). By univariate analysis, preoperative predictors of non-functioning pancreatic endocrine carcinoma included the presence of symptoms (OR 3.96, 95% CI 2.06–7.63) and an increase in the absolute value of radiological diameter (OR 1.05, 95% CI 1.03–1.07). A cystic morphology of the lesion turned out to be a negative predictor of carcinoma (OR 0.25, 95% CI 0.70–0.87). These results were confirmed by multivariable analysis. Conclusions: NF-CPETs have a measurable propensity to be benign. In those patients affected by small and asymptomatic NF-CPET a more conservative surgical approach or a follow-up policy could be considered.

Keywords:
Surgery, Cystic tumors, Pancreatic endocrine tumors, Prognosis
1.
Brugge WR, Lewandrowski K, Lee-Lewandrowski E, Centeno BA, Szydlo T, Regan S, del Castillo CF, Warshaw AL: Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 2004;126:1330–1336.
2.
Le Brogne J: Cystic tumours of the pancreas. Br J Surg 1998;85:577–579.
3.
Brugge WR, Lauwers GY, Sahani D, Fernandez-del Castillo C, Warshaw A: Cystic neoplasms of the pancreas. N Engl J Med 2004;351:1218–1226.
4.
Shrendt SA, Komorowski RA, Demeure MJ, Wilson SD, Pitt HA: Cystic pancreatic neuroendocrine tumors: is preoperative diagnosis possible? J Gastrointest Surg 2002;6:66–74.
5.
Ligneau B, Lombard-Bohas C, Partensky C, Valette PJ, Calender A, Dumortier J, Gouysse G, Boulez J, Napoleon B, Berger F, Chayvialle JA, Scoazec JY: Cystic endocrine tumors of the pancreas: clinical, radiologic, and histopathologic features in 13 cases. Am J Surg Pathol 2001;25:752–760.
6.
Schwartz RW, Munfakh NA, Zweng TN, Strodel WE, Lee E, Thompson NW: Nonfunctioning cystic neuroendocrine neoplasms of the pancreas. Surgery 1994;115:645–649.
7.
Goto M, Nakano I, Sumi K, Yamaguchi H, Kimura T, Sako Y, Nawata H, Tanaka M, Nagai E: Cystic insulinoma and nonfunctioning islet cell tumor in multiple endocrine neoplasia type 1. Pancreas 1994;9:393–395.
8.
Nojima T, Kojima T, Kato H, Inoue K, Nagashima K: Cystic endocrine tumor of the pancreas. Int J Pancreatol 1991;10:65–72.
9.
Thompson NW, Eckhauser FE, Vinik AI, Lloyd RV, Fiddian-Green RG, Strodel WE: Cystic neuroendocrine neoplasms of the pancreas and liver. Ann Surg 1984;199:158–164.
10.
Davtyan H, Nieberg R, Reber HA: Pancreatic cystic endocrine neoplasms. Pancreas 1990;5:230–233.
11.
Sumarac-Dumanovic M, Micic D, Krstic M, Georgiev M, Diklic A, Tatic S, Stamenkovic-Pejkovic D, Kendereski A, Cvijovic G, Pavlovic A: Pitfalls in diagnosing a small cystic insulinoma: a case report. J Med Case Reports 2007;1:181.
12.
Brown K, Kristopaitis T, Yong S, Chejfec G, Pickleman J: Cystic glucagonoma: a rare variant of an uncommon neuroendocrine pancreas tumor. J Gastrointest Surg 1998;2:533–536.
13.
Sarui H, Yoshimoto K, Okumura S, Kamura M, Takuno H, Ishizuka T, Takao H, Shimokawa K, Itakura M, Saji S, Yasuda K: Cystic glucagonoma with loss of heterozygosity on chromosome 11 in multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 1997;46:511–516.
14.
Yagihashi S, Yagihashi N, Nagai KN: Cystic pancreatic glucagonoma in contact with insulinoma found in a hypoglycemic patient. Pathol Res Pract 1992;188:751–756.
15.
Bordeianou L, Vagefi PA, Sahani D, Deshpande V, Rakhlin E, Warshaw AL, Fernandez-del Castillo C: Cystic pancreatic endocrine neoplasms: a distinct tumor type? J Am Coll Surg 2008;206:1154–1158.
16.
Deshpande V, Lauwers GY: Cystic pancreatic endocrine tumor: a variant commonly confused with cystic adenocarcinoma. Cancer 2007;111:47–53.
17.
Goh BK, Ooi LL, Tan YM, Cheow PC, Chung YF, Chow PK, Wong WK: Clinico-pathological features of cystic pancreatic endocrine neoplasms and a comparison with their solid counterparts. Eur J Surg Oncol 2006;32:553–556.
18.
Baker MS, Knuth JL, DeWitt J, LeBlanc J, Cramer H, Howard TJ, Schmidt CM, Lillemoe KD, Pitt HA: Pancreatic cystic neuroendocrine tumors: preoperative diagnosis with endoscopic ultrasound and fine-needle immunocytology. J Gastrointest Surg 2008;12:450–456.
19.
Sahani DV, Kadavigere R, Saokar A, Fernandez-del Castillo C, Brugge WR, Hahn PF: Cystic pancreatic lesions: a simple imaging-based classification system for guiding management. Radiographics 2005;25:1471–1484.
20.
Solcia E, Kloppel G, Sobin LH (in collaboration with 9 pathologists from 4 countries): Histological typing of endocrine tumours; in WHO International Histological Classification of Tumours, ed 2. New York, Springer, 2000.
21.
Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395–401.
22.
Malago R, D’Onofrio M, Zamboni GA, Faccioli N, Falconi M, Boninsegna L, Mucelli RP: Contrast-enhanced sonography of nonfunctioning pancreatic neuroendocrine tumors. AJR Am J Roentgenol 2009;192:424–430.
23.
Vignesh S, Brugge WR: Endoscopic diagnosis and treatment of pancreatic cysts. J Clin Gastroenterol 2008;42:493–506.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.